DRUGphase1antibody
ARGX-119
Mechanism
Anti-MuSK agonist monoclonal antibody. Coadministration with SMN2 splice modulator (SMN-C3) improves voluntary locomotion + masseter force in SMNΔ7 mouse model (Coppejans O28 Budapest 2026). Combination strategy: SMN-restore + NMJ-target.
Related claims (0)
No claims matched “ARGX-119” in free-text search.
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.